Aisa Pharma stories constructive outcomes for AISA-021
Aisa Pharma has reported constructive outcomes from its Section II RECONNOITER trial of AISA-021 (cilnidipine), a once-daily calcium channel blocker, for sufferers with systemic sclerosis-associated Raynaud’s phenomenon (SSc RP).
The findings had been offered on the ninth World Congress on Systemic Sclerosis in Athens, Greece.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra info
The double-blind, randomized, potential crossover, placebo-controlled examine assessed the security and efficacy of every day oral AISA-021 in sufferers with lively SSc RP.
It included 64 sufferers and was carried out in two segments: Half A used a parallel-arm design to evaluate dose (10 mg and 20 mg), efficacy, co-administration, and security with a phosphodiesterase kind 5 (PDE-V) inhibitor; Half B used a crossover design with 37 sufferers.
The first endpoint was the change from baseline within the imply weekly variety of Raynaud’s assaults. Key secondary endpoints included severity, period, Raynaud’s situation rating (RCS), ache and seizure-free days. Sufferers obtained commonplace of care therapies along with AISA-021.
Within the major endpoint evaluation, remedy with AISA-021 led to a 22.1% discount within the imply frequency of patient-reported weekly Raynaud’s assaults in comparison with baseline. Placebo-treated sufferers noticed a 12.4% discount; this distinction didn’t attain statistical significance.
AISA-021 confirmed a major improve within the variety of seizure-free days, a placebo-adjusted improve of over 155% and an almost fourfold enchancment over baseline.
There have been statistically vital reductions in assault period and enhancements in pores and skin temperature on the proximal interphalangeal joint (PIP).
The remedy additionally improved non-Raynaud signs measured by the SHAQ PRO instrument for SSc, demonstrating numerical advantages over placebo in all-cause ache, gastrointestinal dysfunction, incapacity, total illness severity, and respiratory.
Therapy was typically effectively tolerated and no treatment-related critical antagonistic occasions occurred in all teams.
Aisa Pharma plans to fulfill with the US Meals and Drug Administration (FDA) and different regulatory authorities following these Section II outcomes, with the goal of outlining the Section III medical trial and potential regulatory pathway for AISA-021 in SSc RP.
Andrew Sternlicht, Founder and CEO of Aisa Pharma, mentioned: “Raynaud’s phenomenon related to systemic sclerosis stays a extremely burdensome manifestation of scleroderma, with no permitted remedy choices and a major influence on perform and high quality of life.
“Though the Section II trial on this small examine didn’t obtain statistical significance on the first efficacy endpoint, we consider that the constant results noticed with AISA-021 on plenty of key endpoints are very encouraging.
“AISA-021 demonstrated vital enhancements within the variety of attack-free days and assault period of Raynaud’s, which had been higher than these noticed with at present accessible calcium channel blockers. AISA-021 additionally improved ache and different signs of Raynaud’s, whereas sustaining its security profile. These encouraging outcomes present robust help for development to Section III trials.”
